A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone with Standard Care to Treat Vision Loss Associated with Macular Edema Secondary to Branch Retinal Vein Occlusion [...] (SCORE) Study Report 6
09/2009
Journal Article
Authors:
Scott, I.;
Ip, M.;
Van Veldhuisen, P.;
Oden, N.;
Blodi, B.;
Fisher, M.;
Chan, C.;
Gonzalez, V.;
Singerman, L.;
Tolentino, M.;
Group;, S.C.O.R.E.Study Rese
Secondary:
Arch Ophthalmol
Volume:
127
Pagination:
1115-1128
URL:
http://www.ncbi.nlm.nih.gov/pubmed/19167078
Keywords:
Follow-Up Studies; Glucocorticoids; Injections; Laser Coagulation; macular edema; Prospective Studies; retinal vein occlusion; Retreatment; Tomography- Optical Coherence; Triamcinolone Acetonide; Vision Disorders; visual acuity; Vitreous Body
Abstract:
OBJECTIVE: To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with standard care (grid photocoagulation in eyes without dense macular hemorrhage and deferral of photocoagulation until hemorrhage clears in eyes with dense macular hemorrhage) for eyes with vision loss associated with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: Multicenter, randomized clinical trial of 411 participants. Main Outcome Measure Gain in visual acuity letter score of 15 or more from baseline to month 12. RESULTS: Twenty-nine percent, 26%, and 27% of participants achieved the primary outcome in the standard care, 1-mg, and 4-mg groups, respectively. None of the pairwise comparisons between the 3 groups was statistically significant at month 12. The rates of elevated intraocular pressure and cataract were similar for the standard care and 1-mg groups, but higher in the 4-mg group. CONCLUSIONS: There was no difference identified in visual acuity at 12 months for the standard care group compared with the triamcinolone groups; however, rates of adverse events (particularly elevated intraocular pressure and cataract) were highest in the 4-mg group. Application to Clinical Practice Grid photocoagulation as applied in the SCORE Study remains the standard care for patients with vision loss associated with macular edema secondary to BRVO who have characteristics similar to participants in the SCORE-BRVO trial. Grid photocoagulation should remain the benchmark against which other treatments are compared in clinical trials for eyes with vision loss associated with macular edema secondary to BRVO.
